Loyal Equipments Limited has entered into a non-binding Memorandum of Understanding (MOU) with F2N Green Hydrogen Srl, a company based in Italy, dated 25th April 2025.

Drug major Cipla on Friday said it has received approval from the US health regulator to market a generic cancer treatment drug. The company has received the final approval from the US Food and Drug ...

Castrol opened a technology centre in Patalganga equipped with blending and testing capabilities as part of its future plans for advanced EV and data centre testing. Its lubricant business targets ...

Indian pharmaceutical stocks experienced a downturn following Donald Trump's renewed threat to impose tariffs on pharmaceutical imports. The Nifty Pharma index fell by 1.7%, with major companies ...

Global brokerage firm Jefferies, in it latest note on India's Information Technology (IT) sector, warned that growing uncertainty and a potentially worsening business outlook, especially following the ...

Indian Pharmaceutical companies, from Sun Pharma Ltd., to Lupin Ltd., Dr. Reddy's Laboratories Ltd., Aurobindo Pharma Ltd., Gland Pharma Ltd., fell up to 5% on Wednesday, April 9, after US President ...

A number of Indian generic drug manufacturers—including Dr Reddy’s Laboratories, Cipla, Natco Pharma and Alkem, among others—are working on generic versions of semaglutide, which is marketed in the US ...

Lupin, Gland Pharma and Zydus Lifesciences saw significant losses, with shares dropping between 3% and 5%. Sun Pharma and Cipla also experienced declines. Give your business an edge with our leading ...

UAE outlines new tax rule for foreign investors and non-residents: All you need to know The new decision specifies the cases in which a non-resident juridical investor in a Qualifying Investment ...

This move is expected to affect directly or indirectly many Indian corporates, including IT giants TCS and Infosys, automobile firms like Tata Motors, pharmaceutical companies such as Sun Pharma and ...

Cipla's shares ended the day at Rs 1415.25, showing a notable decrease of 5.38% today. Despite today's drop, Cipla has delivered impressive five-year returns of 214.16%, highlighting its long-term ...

Key players witnessed sharp declines: Aurobindo Pharma, Laurus Labs, and IPCA Laboratories fell up to 8 per cent. Lupin, Biocon, and Cipla experienced significant declines. Sun Pharma, Dr. Reddy’s, ...